A 2025 real-world study of 195 patients, posted as a preprint and not yet peer reviewed, found higher response rates with fMRI-guided targeting in accelerated TMS for treatment-resistant depression. Standard-targeted accelerated TMS also helped most patients.
If you've been fighting depression for years and watched medication after medication fail to lift it, the exhaustion and frustration are real. You've probably read about newer treatments and wondered whether any of them would actually work for you, and whether the personalized approaches are worth the extra cost and complexity.
Transcranial magnetic stimulation (TMS) has been FDA-cleared for depression since 2008, and the field has evolved substantially in recent years. New accelerated protocols deliver a full treatment course in five days rather than six weeks, and some clinics have added functional MRI to personalize where the treatment is targeted for each patient.
This article walks through what a recent naturalistic study of 195 patients (a preprint, not yet peer reviewed) can tell you about fMRI-guided accelerated TMS: what it found about outcomes, when standard targeting is still effective, and how the treatment compares to other options. Individual results vary.
Note: A 2025 preprint (not yet peer reviewed) looked back at 195 patients treated with accelerated TMS at one clinic. 77% responded with fMRI-guided targeting and 66% with standard targeting. After the researchers adjusted for differences between the groups, fMRI guidance came out ahead. Most of the authors work for the clinic that ran the study. Individual results vary. Book a free consultation to find out if you're a candidate.
What This Study Examined
A recent naturalistic study analyzed outcomes from 195 adults with treatment-resistant depression who received accelerated TMS between 2018 and 2025. These were not carefully selected research participants. They were patients seeking treatment in a clinical setting, many with multiple failed medication trials and complex medical histories.
The study compared two groups: 115 patients received fMRI-guided targeting to personalize their treatment, while 80 patients received standard scalp-based targeting. Of those 80, 55 were treated with a figure-eight coil placed using the Beam F3 method, which estimates location based on skull landmarks, and 25 were treated with an H-coil.
Before any adjustment, 77.4% of the fMRI-guided group responded, compared with 66.3% of the standard group. After the researchers adjusted for differences between the groups, fMRI guidance was linked to about twice the odds of response (odds ratio 2.13, p=0.038). Odds are not the same as chances: the raw gap in response was about 11 percentage points.
Understanding the Neuroscience: Why Location Matters
To appreciate why personalized targeting might make such a difference, we need to understand a bit about how TMS works and what it's trying to accomplish.
The Brain Networks Behind Depression
Depression isn't caused by a single brain region "malfunctioning." Instead, it involves disrupted communication between multiple brain networks. One of the most important connections is between the dorsolateral prefrontal cortex (DLPFC), located behind your forehead and involved in executive function, emotion regulation, and decision-making, and the subgenual cingulate cortex (SGC), a deeper region that tends to be overactive in depression.
Think of these regions like two cities connected by a highway. In depression, this highway becomes underactive, and the DLPFC isn't properly regulating the SGC's emotional processing. TMS works by stimulating specific spots in the DLPFC to strengthen this connection.
How fMRI Personalizes the Target
Personalization matters because everyone's brain is organized slightly differently. The exact location of the DLPFC that connects most strongly to the SGC varies from person to person.
The DLPFC is a relatively large brain region that is responsible for many functions, so the "ideal" spot to stimulate within the DLPFC to reach the SGC could be a very different location for you than for someone else.
fMRI (functional magnetic resonance imaging) allows clinicians to map your brain's specific connectivity patterns. During a roughly 20-minute scan, patients simply rest while the MRI measures spontaneous fluctuations in brain activity, which show how your brain naturally communicates with itself.
The analysis identifies which locations in your DLPFC show the strongest anti-correlation (negative functional connectivity) with the SGC. This is your personalized target: the precise spot where stimulation is most likely to influence the depression-related network.
The Standard Approach: Beam F3
The DLPFC is a large region with many subregions that do similar, overlapping functions. Most areas of the left DLPFC contribute in lesser and greater degrees to the function of controlling depression. The small spot that is the most anti-correlated with SGC is particularly dedicated to this function, and is the most potent spot to stimulate. However, if you stimulate just about anywhere in the left DLPFC, you will likely get some degree of benefit.
The Beam F3 method relies on this fact for treating many patients effectively without imaging. This method uses skull measurements to estimate where the DLPFC is located, similar to how a tailor might use standard measurements to estimate clothing fit. It accounts for head size variations but doesn't capture the individual differences in where specific brain networks are located.
What "Accelerated" TMS Actually Means
Traditional TMS for depression uses daily sessions over four to six weeks, a significant time commitment. Accelerated TMS compresses this into five days, with 8–10 sessions per day spaced approximately 50 minutes apart. It uses a specific stimulation pattern called intermittent theta-burst stimulation (iTBS), delivers a full treatment course in one week, and enables faster onset of therapeutic effect than traditional protocols.
This acceleration is based on established neuroscience. The brain undergoes neuroplastic changes, or physical rewiring of neural connections, in response to TMS. Multiple daily sessions may reinforce these changes more effectively than sessions spread over weeks. It's similar to how studying with short breaks can be more effective than spreading study sessions far apart. Neural pathways are strengthened while they're still active from the previous session.
The Real-World Results: What the Numbers Mean
Here's what the study found in practical terms.
Overall effectiveness
- 72.8% of all patients responded to treatment within one month (defined as a clinician rating of 2 or better on the Clinical Global Impression - Improvement scale, meaning much or very much improved).
- 51.8% achieved a CGI-I score of 1 (very much improved), which the paper defines as remission. Many of these patients had tried numerous treatments, had comorbid conditions, and represented the real complexity of clinical practice.
The fMRI Advantage
The researchers also used propensity score matching, a statistical technique that pairs similar patients who differed mainly in whether they received fMRI guidance. A standard-targeted patient could be used as a match up to twice, so the 71 matched pairs drew on 45 different standard-targeted patients:
- fMRI-guided: 77.5% response (55 of 71)
- Standard targeting, counted by pair: 53.5% response (38 of 71)
- Standard targeting, counted by person: 62.2% response (28 of 45)
Across the matched pairs, fMRI guidance had 2.3 times the odds of response (p=0.035). The authors estimated about one additional responder for every six or seven people treated with fMRI guidance. Because patients were not randomly assigned, this shows an association, not proof that the scan caused the difference.
Who Responded Best?
In the full group, fMRI guidance was the only factor that independently predicted response. Patients who had tried more antidepressants showed a trend toward lower response that was not statistically significant (p=0.065). It did reach significance among patients treated with a figure-eight coil.
Age, sex, baseline severity, and history of other brain stimulation treatments didn't significantly predict outcomes.
Safety Profile: What About Side Effects?
Treatment was generally well-tolerated, with no patients discontinuing due to adverse events. The most common side effects were headache, fatigue, and treatment-emergent anxiety. Side effects were more common with fMRI guidance: any side effect (p=0.016), headache (p=0.026), cognitive effects (p=0.046), and pain at the stimulation site (p=0.046). The authors wrote that anxiety and physical side effects in the fMRI-guided group were higher than they expected.
In all but two patients, treatment-emergent anxiety went away on its own before the end of the treatment week. The other two improved within a month after right-sided TMS and therapy. For patients who experience treatment-emergent anxiety that persists, adding right-hemisphere stimulation to target the anxiety-related circuit has been documented as a management approach in the literature and is one option available in accelerated TMS programs. Individual results vary.
The study also reported one patient who died by suicide two days after treatment. This patient had been identified as high-risk at baseline with a prior history of suicide gestures, and after review by three board-certified psychiatrists, the death was determined to be unrelated to direct TMS effects. This case is a reminder of the need for ongoing safety monitoring after intensive treatment, particularly for patients who may perceive it as a last-resort intervention.
The Clinical Implications: What This Means for Patients
This study addresses a critical question facing the field: Is the added complexity and cost of fMRI-guided targeting worth it?
This study suggests it may be, with important caveats:
For Patients Considering Treatment
- aTMS helped many patients even without fMRI guidance (66% response before matching; standard targeting can still activate the right area of the DLPFC in many cases)
- fMRI guidance was linked to better odds (77% response)
- The treatment works quickly (most improvement within days to weeks, not months)
- It's appropriate for highly treatment-resistant cases (average 5+ prior medication failures)
The Access Question
Not everyone has access to fMRI-guided TMS, and insurance coverage for TMS varies significantly between standard and accelerated protocols.The technology requires:
- An MRI scanner meeting specific quality standards
- Specialized image processing software and expertise
- Neuronavigation equipment to match the MRI brain map to the patient's actual head
- Clinicians trained in connectivity-based targeting
If fMRI-guided targeting isn't available in your area, this study's findings remain encouraging: standard accelerated TMS still produced a 62-66% response rate, which compares favorably to most antidepressant medications and traditional TMS protocols.
Understanding the Study's Strengths and Limitations
What Makes This Study Valuable
1. Real-world data: Unlike highly controlled clinical trials that exclude patients with comorbidities, this study included the messy reality of clinical practice: patients with multiple diagnoses, prior treatment failures, and varying clinical presentations.
2. Sample size: 195 patients is a much larger group than the first accelerated TMS trials, which enrolled 22 and 29 people.
3. Statistical matching: The researchers used propensity score matching to create "apples-to-apples" comparisons between groups that differed in baseline characteristics.
Important Limitations to Consider
1. Not a randomized trial: Patients were not randomly assigned. fMRI guidance was not offered at the clinic before November 2021, so the two groups were partly treated at different times. While statistical matching helps, unmeasured confounding factors could still influence results.
2. Potential placebo enhancement: Patients receiving fMRI guidance knew they were getting "advanced" personalized treatment, which might enhance placebo response.
3. Temporal bias: fMRI guidance was introduced midway through data collection, so later patients had different treatment experiences than earlier ones.
4. Single-site study: Results from one specialized clinic may not generalize to all settings.
5. Not yet peer reviewed, and run by the treating clinic: The study is a preprint. It was run at Acacia Clinics, which offers this treatment, and eight of the nine authors are paid by that clinic. The senior author, Dr. Shan Siddiqi of Mass General Brigham, consults for the clinic, owns intellectual property on individualized targeting, and holds shares in Magnus Medical, which makes a scan-guided TMS system. Cognitive FX was not involved in the study.
The gold standard for confirming these findings would be a randomized controlled trial where patients are assigned to fMRI-guided vs. standard targeting. A 160-person randomized trial at Brigham and Women's Hospital is registered (NCT07043738), but it had not started recruiting as of November 2026. Randomized results so far are mixed. A UK trial of 255 people (BRIGhTMIND) found that theta burst TMS aimed with a personalized connectivity scan worked about as well as standard TMS at the usual spot over six months. That trial used 20 sessions over four to six weeks, not an accelerated schedule.
The Neuroscience of Precision Psychiatry
This study is part of a push toward what researchers call "precision psychiatry," tailoring treatments to individual brain architecture rather than using one-size-fits-all approaches.
The concept builds on decades of neuroscience research showing that:
- Brain networks, not individual regions, drive psychiatric symptoms
- Network organization varies substantially between individuals
- Interventions targeting specific networks may be more effective than region-based approaches
fMRI-guided TMS applies this idea. Instead of using one scalp location for everyone, it aims at the spot in each person's DLPFC most connected to the subgenual cingulate.
Comparing Accelerated TMS to Other Depression Treatments
These response rates are best understood alongside other treatment-resistant depression options.
These figures come from different studies with different patients and measures, so treat them as a rough guide, not a direct comparison.
Depression is a time-sensitive condition. Symptoms have real costs in relationships, work, and quality of life, so a treatment that produces results in days rather than weeks or months represents a meaningful advance. Individual results vary.
What About Treatment Durability?
One question this study doesn't fully answer: How long do these improvements last?
The outcomes were measured within one month of treatment completion. That shows a fast initial response, but not how long it lasts.
Follow-up data from other accelerated TMS studies are limited. Some patients need additional "booster" sessions, and maintenance schedules are still being studied.
This is an area where ongoing research is needed, and where personalized approaches (like fMRI-guided maintenance targeting) may prove valuable.
The Future of Image-Guided TMS
This study opens several exciting research directions:
-
Symptom-specific targeting: Rather than just targeting "depression," could we identify distinct targets for specific symptoms like anxiety, anhedonia (inability to feel pleasure), or cognitive dysfunction?
-
Biomarker development: Can baseline brain connectivity patterns predict who will respond best to treatment?
-
Multi-target protocols: Should some patients receive stimulation to multiple sites based on their specific symptom profile?
-
Optimization of fMRI acquisition: What's the minimum scan time needed? How does scanner quality affect target selection?
-
Integration with other treatments: How does aTMS combine with psychotherapy, medications, or other neuromodulation approaches?
What This Means for Patients
In this study, 66% of standard-targeted patients and 77% of fMRI-guided patients responded within a month after treatment. Improvement came within days to weeks, in patients who had already tried several antidepressants. Because the study was not randomized and is not yet peer reviewed, it can't prove that the scan caused the difference.
If you are considering treatment, both fMRI-guided and standard-targeted protocols are options worth discussing with a treatment team, based on your specific circumstances, prior treatment history, and access to fMRI-guided providers.
fMRI-Guided Accelerated iTBS at Cognitive FX
Cognitive FX offers fMRI-guided accelerated intermittent theta burst TMS for patients with treatment-resistant depression. It uses the same broad approach as the fMRI-guided group in the study above: functional MRI to find each patient's DLPFC target from its connection to the SGC, an accelerated five-day schedule, and intermittent theta burst stimulation. It is our own protocol, delivered off-label, and has not been tested in a clinical trial. Results from the study above should not be assumed to apply to treatment at Cognitive FX.
What the protocol involves. Treatment starts with a functional MRI scan and a clinical intake with the CFX psychiatric team. The neuroscientist and prescribing physician review the fMRI in-house to identify the specific coordinate in the DLPFC with the strongest anti-correlation to the SGC in that patient. That coordinate becomes the individualized treatment target. Over the following five consecutive days, patients receive 10 iTBS sessions per day, spaced approximately 50 minutes apart, for 50 sessions total. Neuronavigation is used to place the coil on the exact target every session.
How this differs from standard rTMS. Standard rTMS uses a single scalp-based coordinate applied to every patient, spread over four to six weeks of daily sessions. Cognitive FX's protocol uses each patient's own fMRI to identify the individualized target, and compresses the full treatment course into five days. The protocol is off-label for depression (all TMS use for post-concussion syndrome or other conditions is off-label). For depression, standard rTMS is the FDA-cleared indication, but many clinics including Cognitive FX offer accelerated iTBS protocols where clinical evidence supports it.
What the cost and format look like. The current fMRI-guided accelerated iTBS treatment at Cognitive FX is $9,900 for the full five-day course. This is generally self-pay, as insurance coverage for accelerated fMRI-guided protocols is limited. Standard rTMS delivered over four to six weeks is often covered by insurance after failure of multiple antidepressants, and CFX can help patients understand their options.
Who is a candidate. The treatment is appropriate for adults with treatment-resistant depression, defined as depression that has not responded to at least two adequate trials of antidepressant medications. The DeSouza study cohort included patients with an average of more than five prior medication failures, so this treatment approach is being applied to patients with substantial treatment resistance.
Who is not a candidate. Cognitive FX does not offer this treatment to patients with metallic implants in the head or neck (including cochlear implants, aneurysm clips, or internal pulse generators), patients with a history of seizures or high seizure risk, patients who are pregnant, or patients in acute psychiatric crisis requiring immediate hospitalization. Bipolar patients may be candidates but require careful individual assessment. During the free consultation, the clinical team reviews each patient's medical history and symptom picture to determine fit before treatment is scheduled.
How it integrates with other care. The accelerated iTBS protocol addresses one component of depression treatment: brain network dysfunction identifiable on imaging. Many patients also benefit from continued psychotherapy, medication management with their existing prescriber, and other supportive care. The treatment is not a replacement for these; it is a targeted intervention that can be combined with them.
How the treatment is scheduled. The process starts with a free consultation with the Cognitive FX team. The consultation reviews your medical history, prior treatments, current symptoms, and treatment preferences to determine whether the fMRI-guided approach is likely to fit your case. If treatment is appropriate, the intake team coordinates the pre-treatment scan, the five-day intensive schedule, travel logistics for out-of-state patients, and follow-up care. Individual results vary.
Conclusion: Personalization Matters, But Access Matters Too
This preprint adds real-world evidence that fMRI-guided targeting may improve response to accelerated TMS. Response was 77% with fMRI guidance and 66% without, and after adjustment and matching, fMRI guidance came out ahead. The study was not randomized, is not yet peer reviewed, and was run by a clinic that offers the treatment, so randomized trials need to confirm it.
Standard-targeted accelerated TMS also helped most patients in this study, which matters for people who can't reach a clinic that offers fMRI guidance.
For patients with treatment-resistant depression, accelerated TMS with or without fMRI guidance may offer benefits where previous treatments have not. Individual results vary.
If persistent depression hasn't responded to multiple medication trials, fMRI-guided accelerated iTBS may help. Take our brief assessment to see if you're a candidate, schedule a free consultation, or call us at 385-334-6093 to speak with our team. Individual results vary.
Further Reading
References
- DeSouza DD, Meng NF, DeGaetano NP, Nakano E, Hoang V, Nguyen T, Ling DS, Carreon DM, Siddiqi SH. Naturalistic Outcomes with fMRI-Guided and Non-fMRI-Guided Accelerated TMS for Depression. medRxiv(preprint, not yet peer-reviewed). 2025. doi:10.1101/2025.09.03.25334813
- Morriss R, Briley PM, Webster L, et al. Connectivity-guided intermittent theta burst versus repetitive transcranial magnetic stimulation for treatment-resistant depression: a randomized controlled trial. Nat Med. 2024;30(2):403-413. doi:10.1038/s41591-023-02764-z
Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report. Am J Psychiatry. 2006;163(11):1905–1917. doi:10.1176/ajp.2006.163.11.1905
- Cole EJ, Stimpson KH, Bentzley BS, et al. Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression. Am J Psychiatry. 2020;177(8):716–726. doi:10.1176/appi.ajp.2019.19070720
- Cole EJ, Phillips AL, Bentzley BS, et al. Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial. Am J Psychiatry. 2022;179(2):132–141. doi:10.1176/appi.ajp.2021.20101429
- Fox MD, Buckner RL, White MP, Greicius MD, Pascual-Leone A. Efficacy of transcranial magnetic stimulation targets for depression is related to intrinsic functional connectivity with the subgenual cingulate. Biol Psychiatry.2012;72(7):595–603. doi:10.1016/j.biopsych.2012.04.028
- Beam W, Borckardt JJ, Reeves ST, George MS. An efficient and accurate new method for locating the F3 position for prefrontal TMS applications. Brain Stimulation. 2009;2(1):50–54. doi:10.1016/j.brs.2008.09.006
- Williams NR, Sudheimer KD, Bentzley BS, et al. High-dose spaced theta-burst TMS as a rapid-acting antidepressant in highly refractory depression. Brain. 2018;141(3):e18. doi:10.1093/brain/awx379
- O'Reardon JP, Solvason HB, Janicak PG, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry. 2007;62(11):1208–1216. doi:10.1016/j.biopsych.2007.01.018
- Carpenter LL, Janicak PG, Aaronson ST, et al. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depress Anxiety.2012;29(7):587–596. doi:10.1002/da.21969
- UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet. 2003;361(9360):799–808. doi:10.1016/S0140-6736(03)12705-5